DK1379246T3 - Nocieptin-analoger - Google Patents

Nocieptin-analoger

Info

Publication number
DK1379246T3
DK1379246T3 DK02764236T DK02764236T DK1379246T3 DK 1379246 T3 DK1379246 T3 DK 1379246T3 DK 02764236 T DK02764236 T DK 02764236T DK 02764236 T DK02764236 T DK 02764236T DK 1379246 T3 DK1379246 T3 DK 1379246T3
Authority
DK
Denmark
Prior art keywords
nocieptin
analogs
orl1
modulators
pain
Prior art date
Application number
DK02764236T
Other languages
Danish (da)
English (en)
Inventor
Qun Sun
R Richard Goehring
Donald Kyle
Zhengming Chen
Sam Victory
John Whitehead
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1379246(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1379246T3 publication Critical patent/DK1379246T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Finishing Walls (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
DK02764236T 2001-04-18 2002-04-18 Nocieptin-analoger DK1379246T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28466601P 2001-04-18 2001-04-18
US28466901P 2001-04-18 2001-04-18
US28466801P 2001-04-18 2001-04-18
US28466701P 2001-04-18 2001-04-18
PCT/US2002/012351 WO2002085357A1 (fr) 2001-04-18 2002-04-18 Analogues de la nociceptine

Publications (1)

Publication Number Publication Date
DK1379246T3 true DK1379246T3 (da) 2009-01-26

Family

ID=27501377

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02764236T DK1379246T3 (da) 2001-04-18 2002-04-18 Nocieptin-analoger
DK05014115.9T DK1598338T5 (da) 2001-04-18 2002-04-18 1-(4-piperidinyl)-1,3-dihydro-2H-indol-2-on-derivater og relaterede forbindelser som nociceptinanaloger og ORL1-ligander til behandlingen af smerte
DK05014117T DK1598340T3 (da) 2001-04-18 2002-04-18 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazol -2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1 ligander til behandling af smerte
DK05014116T DK1598339T3 (da) 2001-04-18 2002-04-18 1-(4-amino-cyclohexyl)-1,3-dihydro-2H-benzimidazol-2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1-ligander til behandling af smerte

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK05014115.9T DK1598338T5 (da) 2001-04-18 2002-04-18 1-(4-piperidinyl)-1,3-dihydro-2H-indol-2-on-derivater og relaterede forbindelser som nociceptinanaloger og ORL1-ligander til behandlingen af smerte
DK05014117T DK1598340T3 (da) 2001-04-18 2002-04-18 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazol -2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1 ligander til behandling af smerte
DK05014116T DK1598339T3 (da) 2001-04-18 2002-04-18 1-(4-amino-cyclohexyl)-1,3-dihydro-2H-benzimidazol-2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1-ligander til behandling af smerte

Country Status (25)

Country Link
US (4) US6867222B2 (fr)
EP (7) EP1598339B1 (fr)
JP (4) JP4364513B2 (fr)
KR (2) KR100847296B1 (fr)
CN (1) CN100352816C (fr)
AT (4) ATE434607T1 (fr)
AU (1) AU2002307416B2 (fr)
BR (1) BR0209129A (fr)
CA (1) CA2444198C (fr)
CL (2) CL2009001278A1 (fr)
CY (4) CY1108707T1 (fr)
CZ (1) CZ20032850A3 (fr)
DE (4) DE60231257D1 (fr)
DK (4) DK1379246T3 (fr)
ES (4) ES2329252T3 (fr)
HU (1) HUP0401109A3 (fr)
IL (4) IL158484A0 (fr)
MX (1) MXPA03009600A (fr)
NO (1) NO20034661L (fr)
NZ (5) NZ540235A (fr)
PL (1) PL367310A1 (fr)
PT (4) PT1598338E (fr)
SI (4) SI1598338T1 (fr)
WO (1) WO2002085357A1 (fr)
YU (1) YU82303A (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6615189B1 (en) * 1998-06-22 2003-09-02 Bank One, Delaware, National Association Debit purchasing of stored value card for use by and/or delivery to others
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
WO2004064835A1 (fr) * 2003-01-17 2004-08-05 Neurosearch A/S Utilisation d'agents de modulation du canal ionique pour traiter la douleur
JP5229853B2 (ja) 2003-02-28 2013-07-03 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な新規な二環尿素誘導体
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2005075459A1 (fr) * 2004-02-03 2005-08-18 Euro-Celtique S.A. Synthese de cyanoimino-benzoimidazoles
WO2006080519A1 (fr) * 2005-01-31 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Derive diamine
WO2007039462A2 (fr) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Derives d'indane utilises comme antagonistes du recepteur mch
JP2009523816A (ja) * 2006-01-19 2009-06-25 アボット・ラボラトリーズ ２−イミノ−ベンズイミダゾール類
EP1987009A1 (fr) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Composes cyclo-uree utilises en tant que bloqueurs des canaux calciques
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080287479A1 (en) * 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
KR101370434B1 (ko) * 2007-01-16 2014-03-06 시오노기세이야쿠가부시키가이샤 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
MX2009009355A (es) * 2007-03-01 2009-09-11 Mitsubishi Tanabe Pharma Corp Compuesto de bencimidazol y uso farmaceutico del mismo.
KR20140139125A (ko) 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
JP2010538985A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 抗ｈｉｖ剤としての副甲状腺ホルモン（１−３４）の使用
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
HRP20120841T4 (hr) 2008-07-21 2015-07-03 Purdue Pharma L.P. Premošteni piperidinski spojevi substituiranog kinoksalin-tipa i njihova uporaba
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
RU2560729C2 (ru) 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов
MX2014005068A (es) 2011-10-28 2014-07-30 Merck Sharp & Dohme Compuestos de benzoxazolinona con actividad selectiva en canales de sodio activados por voltaje.
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2014102594A2 (fr) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations
WO2014102588A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type indole et indoline et leurs utilisations
WO2014102589A1 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine du type quinazolin-4(3h)-one et utilisations de ceux-ci
WO2014102590A1 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de type pipéridine-4-amino substituée et leurs utilisations
AU2013369649B2 (en) 2012-12-31 2018-07-26 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
EP4455145A3 (fr) * 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Composés de récepteur de la pipéridinyl nociceptine
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171360A (en) * 1875-12-21 Improvement in mortising-machines
US49212A (en) * 1865-08-08 Improvement in submerged force-pumps
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3325499A (en) 1964-11-02 1967-06-13 Mcneilab Inc 1-(1-hydrocarbyl-4-piperdyl)-2-indolinone
US3325490A (en) * 1965-02-23 1967-06-13 Rexall Drug Chemical Substituted 1-hydroxydibenzopyrans
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4410528A (en) * 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
DE3827641A1 (de) * 1988-08-16 1990-03-08 Basf Ag 2,6-polyalkylpiperidinsubstituierte bislactame und deren verwendung zum stabilisieren von organischem material, insbesondere von kunststoffen und damit stabilisiertes material
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
CA2187767A1 (fr) * 1994-04-14 1995-10-26 Joel R. Huff Antagonistes du recepteur adrenergique alpha1c
FR2722190B1 (fr) 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
EP0786997A4 (fr) * 1994-10-27 1998-03-11 Merck & Co Inc Antagonistes de muscarine
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
GB9603457D0 (fr) * 1996-02-19 1996-04-17 Merck & Co Inc
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
WO1996041626A1 (fr) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprenant un inhibiteur de cyclooxygenase-2 et un inhibiteur de 5-lipoxygenase
CA2231773A1 (fr) 1995-09-13 1997-03-20 Shigeru Aono Derives de phenylpiperidine
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ332245A (en) * 1996-03-30 2000-03-27 Roche Diagnostics Gmbh Substituted benzo-oxazolol carboxylic acid derivatives, process for their production and medicaments containing them
CA2249601A1 (fr) * 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibiteurs de la farnesyl-proteine transferase
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6180649B1 (en) 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9807083A (pt) 1997-01-23 2000-04-18 Smithkline Beckman Corp Antagonistas ao receptor de il-8
US6117973A (en) * 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6258825B1 (en) * 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
JPH10330377A (ja) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
CA2298813A1 (fr) * 1997-08-28 1999-03-04 Merck & Co., Inc. Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine
EP0921125B1 (fr) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag Derives de la 1,3,8-triazaspiro[4,5]decan-4-one
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
ES2175925T3 (es) 1998-01-19 2002-11-16 Pfizer Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
EP1080091A1 (fr) 1998-05-18 2001-03-07 Novo Nordisk A/S Nouvelles 1,3,8-triazaspiro[4.5]decanones possedant une affinite elevee pour les sous-types du recepteur opioide
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) * 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
KR20010079778A (ko) 1998-09-09 2001-08-22 이시하라 겐조 제초제로 유용한 융합-벤젠 유도체
AR021968A1 (es) 1998-12-23 2002-09-04 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
AU1691500A (en) * 1998-12-24 2000-07-31 Meiji Seika Kaisha Ltd. Remedies for pain
JP4011819B2 (ja) * 1999-04-12 2007-11-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 インドール誘導体の製造法およびその中間体
EP1106605A4 (fr) 1999-06-24 2005-12-07 Toray Industries Antagonistes du recepteur adrenergique-alpha1b
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
CZ2002233A3 (cs) * 1999-07-21 2002-04-17 Fujisawa Pharmaceutical Co., Ltd. Benzimidazolonové deriváty, způsob jejich výroby a farmaceutický prostředek
EP1242085B1 (fr) * 1999-12-06 2005-08-24 Euro-Celtique, S.A. Composes de benzimidazole a affinite vis-a-vis du recepteur de la nociceptine
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
DE60023100T2 (de) 2000-01-05 2006-07-06 Pfizer Inc. Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten
ES2248281T3 (es) * 2000-02-18 2006-03-16 Meiji Seika Kaisha, Ltd. Derivados de fenoxialquilamina utiles como agonistas del receptor opioide delta.
AU2001238690A1 (en) * 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
AU2001242744B2 (en) * 2000-03-24 2005-07-21 Meiji Seika Kaisha Ltd Diphenylalkylamine derivatives useful as opioid delta receptor ligands
ATE405543T1 (de) 2000-05-29 2008-09-15 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung von stickstoffverbindungen
EP1167969A2 (fr) 2000-06-14 2002-01-02 Pfizer Inc. Méthode et système pour la prédiction des propriétés pharmacocinétiques
RU2317988C2 (ru) * 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
DE60136546D1 (de) * 2000-09-06 2008-12-24 Ortho Mcneil Pharm Inc Methode zum bekämpfen der allergien durch verwendung von substituierten pyrazolen
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
BR0209129A (pt) * 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
US7476688B2 (en) 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
EP1451173A4 (fr) 2001-11-01 2005-10-26 Icagen Inc Piperidines

Also Published As

Publication number Publication date
NO20034661L (no) 2003-12-17
PT1379246E (pt) 2009-01-14
ES2322158T3 (es) 2009-06-17
KR20060127421A (ko) 2006-12-12
CY1108707T1 (el) 2014-04-09
US7495109B2 (en) 2009-02-24
DE60232752D1 (de) 2009-08-06
ATE423098T1 (de) 2009-03-15
EP1598338A1 (fr) 2005-11-23
EP1918279A3 (fr) 2008-07-16
EP1379246A1 (fr) 2004-01-14
NZ540233A (en) 2007-02-23
DE60229224D1 (de) 2008-11-20
CA2444198C (fr) 2010-06-22
IL158484A (en) 2010-12-30
CZ20032850A3 (cs) 2004-02-18
EP1598339A1 (fr) 2005-11-23
KR20030096328A (ko) 2003-12-24
CA2444198A1 (fr) 2002-10-31
JP5189562B2 (ja) 2013-04-24
HUP0401109A2 (hu) 2004-09-28
SI1598339T1 (sl) 2009-12-31
IL208903A0 (en) 2011-01-31
SI1379246T1 (sl) 2009-04-30
NZ551453A (en) 2008-02-29
MXPA03009600A (es) 2004-04-02
PT1598338E (pt) 2009-05-08
IL208907A (en) 2012-09-24
US20050159452A1 (en) 2005-07-21
CL2009001278A1 (es) 2009-10-09
EP1598338B1 (fr) 2009-02-18
SI1598340T1 (sl) 2009-08-31
IL208907A0 (en) 2011-01-31
EP1918279A2 (fr) 2008-05-07
DK1598340T3 (da) 2009-05-11
NZ540235A (en) 2007-01-26
DK1598338T3 (da) 2009-06-08
KR100847296B1 (ko) 2008-07-23
EP1598338B9 (fr) 2009-11-18
JP2009263379A (ja) 2009-11-12
US20090156640A1 (en) 2009-06-18
ES2329252T3 (es) 2009-11-24
HUP0401109A3 (en) 2007-12-28
CN100352816C (zh) 2007-12-05
US6867222B2 (en) 2005-03-15
HK1088892A1 (en) 2006-11-17
US8252815B2 (en) 2012-08-28
ATE434607T1 (de) 2009-07-15
CL2009001279A1 (es) 2009-11-27
US20030069249A1 (en) 2003-04-10
ATE410165T1 (de) 2008-10-15
EP1379246B1 (fr) 2008-10-08
DE60231442D1 (de) 2009-04-16
JP2009263378A (ja) 2009-11-12
JP2009263380A (ja) 2009-11-12
EP1379246A4 (fr) 2005-09-28
NZ528977A (en) 2005-10-28
NZ540234A (en) 2007-01-26
ES2323876T3 (es) 2009-07-27
EP2050450A1 (fr) 2009-04-22
CN1561211A (zh) 2005-01-05
DK1598338T5 (da) 2010-01-18
AU2002307416B2 (en) 2005-08-11
PT1598339E (pt) 2009-09-03
JP2005518330A (ja) 2005-06-23
EP1598340B1 (fr) 2009-03-04
CY1109092T1 (el) 2014-07-02
WO2002085357A1 (fr) 2002-10-31
KR100878774B1 (ko) 2009-01-14
EP1930322A1 (fr) 2008-06-11
US7939670B2 (en) 2011-05-10
US20120095049A1 (en) 2012-04-19
JP4364513B2 (ja) 2009-11-18
EP1598339B1 (fr) 2009-06-24
BR0209129A (pt) 2005-12-20
HK1063149A1 (en) 2004-12-17
YU82303A (sh) 2006-03-03
ES2315394T3 (es) 2009-04-01
EP1598340A1 (fr) 2005-11-23
HK1086000A1 (en) 2006-09-08
IL158484A0 (en) 2004-05-12
NO20034661D0 (no) 2003-10-17
PL367310A1 (en) 2005-02-21
DE60231257D1 (de) 2009-04-02
SI1598338T1 (sl) 2009-06-30
HK1088891A1 (en) 2006-11-17
DK1598339T3 (da) 2009-09-28
JP5081870B2 (ja) 2012-11-28
ATE424385T1 (de) 2009-03-15
CY1109053T1 (el) 2014-07-02
IL208903A (en) 2012-07-31
PT1598340E (pt) 2009-04-13
CY1109352T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
DE60229224D1 (de) Nociceptin-analoga
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
SE0400043D0 (sv) New compounds
NO20054476L (no) Forbindelser for behandling av smerte
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
SE0101082D0 (sv) Novel use
NO20033804L (no) Karbamatforbindelser for behandling av smerte
BR0309708A (pt) Compostos como moduladores de receptor de opióde
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
GB0328295D0 (en) Therapeutic compounds
BR0214244A (pt) Uso de uma ascomicina
EA200801392A1 (ru) Соединения 4-оксадиазолил-пиперидина и их применение
ITMI20022723A1 (it) Composizioni per il trattamento della sindrome post-menopausa.
TW200603801A (en) Novel dialkoxy-imidazopyridines